Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10154862 | 0.88 | HRH3 (0.37) | HRH3GAAHRH1HTR6KDM4E | |
| SCHEMBL10154859 | 0.87 | GRIN2B (0.37) | HRH3GAAHRH1HTR6KDM4E | |
| SCHEMBL8027789 | 0.83 | GAA (0.52) | CHRM2CHRM1CHRM3HRH3GAA | |
| SCHEMBL10127858 | 0.83 | GAA (0.52) | CHRM2CHRM1CHRM3HRH3GAA | |
| SCHEMBL8021826 | 0.83 | GAA (0.52) | CHRM2CHRM1CHRM3HRH3GAA | |
| SCHEMBL8032476 | 0.82 | ALDH1A1 (0.42) | HRH3GAAHTR6KDM4EALDH1A1 | |
| SCHEMBL10154853 | 0.81 | HRH3 (0.40) | HRH3GAAHRH1HTR6KDM4E | |
| SCHEMBL14216279 | 0.80 | HRH3 (0.39) | HRH3GAAHRH1HTR6THRB | |
| SCHEMBL14258735 | 0.79 | THRB (0.44) | CHRNB2CHRNA4GAATHRBKDM4E | |
| SCHEMBL10154855 | 0.79 | ALDH1A1 (0.53) | GAAHTR6THRBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | BORISOVICH FROLOV YEVGENIY (RU) | 2012-02-16 | — | — | US | disclosed |
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | IVASHCHENKO ANDREY ALEXANDROVICH | 2011-02-24 | — | — | US | disclosed |
| EP-2184064-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | Alla Chem, LLC. (US) | 2010-05-12 | — | — | EP | disclosed |
| WO-2008060190-A2 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008024029-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ALLA CHEM, LLC (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040965-A1 | SUBSTITUTED AZEPINO[4,3-B]INDOLES, PHARMACOLOGICAL COMPOSITION AND A METHOD FOR THE PRODUCTION AND USE THEREOF | ABCG2, HTR3C, AADAC | CHRM2 113/4885CHRM1 18/4885CHRNB2 1242/4885 |
| US-20110046368-A1 | LIGANDS OF 5-HT6 RECEPTORS, A PHARMACEUTICAL COMPOSITION, METHOD FOR THE PRODUCTION AND USE THEREOF | HTR6, HTR1A, HTR3B | CHRM2 35/4885CHRM1 32/4885CHRNB2 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.